
The European Commission has signed off on Amgen’s Repatha, making it the first in a new class of cholesterol-lowering drugs …

Praluent, the new heart drug from Sanofi and Regeneron, has met its primary endpoint in a Phase III study in …
Sanofi and Regeneron’s anti-cholesterol drug has impressed in a mid-stage trial, and will now progress into Phase III. The firms’ …

